Associations - HER-2 mutation

HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Front Oncol - 2 weeks
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials J Thorac Oncol - 3 weeks
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	afatinib Resistant: A2 - Guideline
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	trastuzumab Resistant: A2 - Guideline
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	ado-trastuzumab emtansine Sensitive: A2 - Guideline
HER-2 mutation HER-2 mutation	Solid Tumor Solid Tumor	BDTX-189 Sensitive: B - Late Trials
HER-2 mutation HER-2 mutation	Breast Cancer Breast Cancer	ribociclib Sensitive: B - Late Trials
HER-2 mutation HER-2 mutation	Solid Tumor Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Gastric Cancer Gastric Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Lung Cancer Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Urothelial Cancer Urothelial Cancer	afatinib Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Solid Tumor Solid Tumor	pyrotinib Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Cervical Cancer Cervical Cancer	neratinib Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	pyrotinib Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Breast Cancer Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Breast Cancer Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	trastuzumab + neratinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	neratinib + temsirolimus Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	U3-1402 Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Biliary Tract Cancer Biliary Tract Cancer	neratinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Thymic Carcinoma Thymic Carcinoma	pyrotinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Solid Tumor Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Colorectal Cancer CRC	pyrotinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Resistant: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials
HER-2 mutation HER-2 mutation	Colorectal Cancer CRC	fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	ado-trastuzumab emtansine Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials
HER-2 mutation HER-2 mutation	Gastric Cancer Gastric Cancer	trastuzumab Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Gastric Cancer Gastric Cancer	RC48 Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Uterine Cancer Uterine Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Cholangiocarcinoma Cholangiocarcinoma	trastuzumab Resistant: C4 – Case Studies
HER-2 mutation HER-2 mutation	Cholangiocarcinoma Cholangiocarcinoma	lapatinib Resistant: C4 – Case Studies
HER-2 mutation HER-2 mutation	Ovarian Cancer Ovarian Cancer	dasatinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	Ovarian Cancer Ovarian Cancer	neratinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	dasatinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	neratinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	dasatinib + neratinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	Ovarian Cancer Ovarian Cancer	dasatinib + neratinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	Cervical Cancer Cervical Cancer	afatinib Sensitive: D – Preclinical